Mendus: Adjusting our estimates for ilixadencel - Redeye
Redeye adjusts its estimates after Institut Bergonié terminated the collaboration agreement to explore ilixadencel combination therapy as part of the REGOMUNE trial.
ANNONS
Redeye adjusts its estimates after Institut Bergonié terminated the collaboration agreement to explore ilixadencel combination therapy as part of the REGOMUNE trial.
